Search results for: Pricing and Reimbursement
Filter search results
Is There Societal Support for an End of Life Premium?
8 May 2017
…to address some of the limitations and ambiguities in the earlier research on this topic. Koonal highlighted three innovative studies led by researchers in the Netherlands, Denmark and Scotland. The…
New OHE Seminar Briefing: Interventions that Encourage High-value Nursing Home Care: Lessons for the UK
11 August 2017
…pricing is not free; consumers with dementia and cognitive impairment are not be full informed; supply is constrained; and the system is fragmented. However, the US is beginning to embrace…
OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
7 September 2018
…financialisation and the obligation to maximise shareholder value through profit, the pharmaceutical sector is increasingly under pressure to deliver short-term financial returns through raising drug prices and executing share buybacks…
OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer
4 October 2018
…will be hosting two lunchtime seminars this month. OHE Lunchtime Seminar with Steven Pearson on ‘Early experience with HTA of gene therapies in the US: pricing and paying for cures’….
OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?
19 August 2019
…outcomes. The weakness is that ‘value’ is not clearly defined and outcome measures focus on issues that are primarily of interest to clinicians and not patients. An alternative outcomes model…
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
…systems and from the availability of treatments. These are over and above any value to the health system from decision makers having greater certainty about the benefits and costs of…
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
…tests, treatments and vaccines will take time and requires rewarding the engagement of private sector research, development and manufacturing, as well using the resources and skills of government and of…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…painfully reveals the broad and disastrous health, economic and societal impact of a highly infectious and potentially deadly disease for which there is, as yet, no vaccine. In addition to…
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
…The Pharmaceutical Industry and Global Health: Facts and Figures 2017. (downloaded from https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf) Barrenho, E. and Miraldo, M., 2018. R&D Success in Pharmaceutical Markets: A Duration Model Approach. In: Health…